Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 4Carcinoid Tumor 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Adenoma, Islet Cell 1Adenocarcinoma 1Acromegaly 1

Interventions

lutetium Lu 177 dotatate 2Sunitinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Everolimus 2sargramostim 1sapanisertib 1pentetreotide 1pasireotide 1napabucasin 1montanide ISA 51 1irinotecan sucrosofate 1incomplete Freund's adjuvant 1fludarabine phosphate 1aflibercept 1Taxes 1Sorafenib 1Salts 1Paclitaxel 1Oxaliplatin 1Octreotide 1Leucovorin 1Irinotecan 1Interleukin-13 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenoma, Islet Cell × pasireotide × Clear all
NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
22 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡